Puma Biotechnology (NASDAQ:PBYI) Insider Douglas Hunt Sells 3,973 Shares of Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Douglas Hunt sold 3,973 shares of Puma Biotechnology stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $5.84, for a total transaction of $23,202.32. Following the transaction, the insider owned 160,921 shares of the company’s stock, valued at $939,778.64. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Puma Biotechnology Stock Performance

Shares of NASDAQ:PBYI opened at $6.20 on Friday. The company’s 50-day moving average is $5.42 and its 200 day moving average is $4.77. Puma Biotechnology, Inc. has a fifty-two week low of $2.58 and a fifty-two week high of $6.29. The company has a market capitalization of $312.42 million, a P/E ratio of 8.38 and a beta of 1.19.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.12. The company had revenue of $54.48 million during the quarter, compared to analysts’ expectations of $51.00 million. Puma Biotechnology had a return on equity of 36.17% and a net margin of 17.45%. As a group, research analysts predict that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analysts Set New Price Targets

PBYI has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings lowered shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Puma Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Puma Biotechnology News Roundup

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: PBYI has moved above its 200‑day moving average, a technical breakout that can attract momentum and trend‑following buyers and supports upward pressure on the share price. Puma Biotechnology Stock Passes Above 200 Day Moving Average
• Neutral Sentiment: Puma disclosed inducement equity awards granted to new hires under Nasdaq Rule 5635(c)(4). These grants are a common hiring tool; they can create modest dilution over time but are typically not material to near‑term trading unless large. Puma Biotechnology Reports Inducement Awards
• Negative Sentiment: Insider selling by senior executives may temper sentiment: CEO Alan A. Auerbach sold a total of 34,950 shares across Jan. 6–7 at ~ $5.84–$5.88, and director Douglas M. Hunt sold 8,987 shares over the same dates at similar prices. While insiders still hold large positions, these disclosed sales can be perceived negatively by some investors as reduced insider conviction or simply personal liquidity events. Auerbach SEC Filing Hunt SEC Filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Kapitalo Investimentos Ltda bought a new stake in shares of Puma Biotechnology during the second quarter valued at approximately $241,000. Acorn Capital Advisors LLC increased its position in Puma Biotechnology by 4.9% during the second quarter. Acorn Capital Advisors LLC now owns 4,131,299 shares of the biopharmaceutical company’s stock worth $14,170,000 after acquiring an additional 191,247 shares during the period. Ethic Inc. acquired a new stake in shares of Puma Biotechnology in the 2nd quarter valued at approximately $51,000. Strs Ohio bought a new position in Puma Biotechnology during the first quarter worth $420,000. Finally, Ritholtz Wealth Management acquired a new position in Puma Biotechnology during the second quarter worth $676,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.